Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Recruiting

Phase 3

Docetaxel & ApalutamideTesting the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT06931340

Conditions

Castration-Sensitive Prostate Carcinoma

Metastatic Prostate Adenocarcinoma

Stage IVB Prostate Cancer AJCC v8

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Androgen Therapy

Apalutamide

Docetaxel

Computed Tomography

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-29. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-10-27.